The Asia-Pacific Laboratory Developed Tests Market was valued at USD 2.72 billion in 2024, and is projected to reach USD 3.94 billion by 2030, rising at a CAGR of 6.40%. The region is witnessing a significant surge in cancer incidence, with an estimated 3.25 million new cases in China in 2024, 1 million new cases in Japan annually, and a projected 1.5 million cases in India by 2025. This trend has created a substantial demand for specialized diagnostic tests, driving the development of laboratory-developed tests (LDTs) tailored to specific patient needs and conditions.
China's implementation of Order 739 in 2021 has facilitated increased development of LDTs, while regulatory reforms in Japan, India, and Australia aim to streamline the approval process for diagnostics, including LDTs. Moreover, significant investments in laboratory automation technologies have enhanced efficiency and accuracy in testing procedures, making LDTs more appealing to healthcare providers.
The growing trend towards automation in laboratories has been pronounced in major hospitals in China and Japan, with adoption rates increasing by approximately 15% annually. Collaborative initiatives among academic institutions, research centers, and healthcare organizations in countries such as Japan and South Korea are driving innovation, enhancing the quality of diagnostic tests, and supporting market growth.
This product will be delivered within 1-3 business days.
China's implementation of Order 739 in 2021 has facilitated increased development of LDTs, while regulatory reforms in Japan, India, and Australia aim to streamline the approval process for diagnostics, including LDTs. Moreover, significant investments in laboratory automation technologies have enhanced efficiency and accuracy in testing procedures, making LDTs more appealing to healthcare providers.
The growing trend towards automation in laboratories has been pronounced in major hospitals in China and Japan, with adoption rates increasing by approximately 15% annually. Collaborative initiatives among academic institutions, research centers, and healthcare organizations in countries such as Japan and South Korea are driving innovation, enhancing the quality of diagnostic tests, and supporting market growth.
Asia Pacific Laboratory Developed Tests Market Report Highlights
- Based on technology, molecular diagnostics dominated the market with a revenue share of 20.0% in 2024, owing to its vital role in rapid pathogen detection and timely treatment decisions.
- Immunoassays are expected to grow at the fastest CAGR over the forecast period.
- Based on application, the oncology segment led the market in 2024, underscoring the need for advanced diagnostics such as LDTs. Innovations such as NGS and PCR have enhanced cancer diagnostics.
- Nutritional and metabolic diseases are projected to witness the fastest CAGR from 2025 and 2030. As aging populations in countries such as Japan and China are more vulnerable to these conditions, increasing the demand for specialized assessments.
- Based on region, China held the largest revenue share in the Asia Pacific laboratory-developed tests market in 2024, fueled by government initiatives and advancements in diagnostics, addressing the rising demand for personalized healthcare solutions for China’s aging population.
- In May 2024, Guardant Health secured EU IVDR certification for Guardant360 CDx in Europe, facilitating expanded genomic profiling of solid tumors and potentially prompting similar regulatory developments in Asia Pacific countries.
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19's impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Asia Pacific Laboratory Developed Tests Market Variables, Trends, & Scope
Chapter 4. Asia Pacific Laboratory Developed Tests Market: Technology Business Analysis
Chapter 5. Asia Pacific Laboratory Developed Tests Market: Application Business Analysis
Chapter 6. Asia Pacific Laboratory Developed Tests Market: Country Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Asia-Pacific Laboratory Developed Tests market report include:- Quest Diagnostics Incorporated
- Abbott
- Guardant Health
- NeoGenomics Laboratories
- Siemens Healthcare Private Limited
- QIAGEN
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.72 Billion |
| Forecasted Market Value ( USD | $ 3.94 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 9 |
